SCHEDULE: Flora Growth CEO Boosts Stake with New Stock Options

Flora Growth Corp.'s CEO, Daniel Reis-Faria, was granted 471,208 stock options with an exercise price of $7.31, vesting upon specific volume-weighted average price thresholds.

Summary

• Daniel Reis-Faria, Chief Executive Officer of Flora Growth Corp., beneficially owns 6,425,951 common shares, representing 88.3% of the class.
• On December 19, 2025, Reis-Faria was granted 471,208 stock options.
• The stock options are exercisable for shares of common stock at an exercise price of $7.31 per share.
• The options vest in five equal installments (20% each) subject to the Issuer's common stock meeting specific volume-weighted average price (VWAP) thresholds: $10.97, $14.62, $18.28, $21.93, and $25.59.

Sentiment

Score: 7

Explanation: The grant of performance-based stock options to the CEO, coupled with his substantial existing ownership, suggests strong alignment of interests and an incentive for future growth, although the future date for the event is unusual for a 13D amendment.

Positives

• CEO Daniel Reis-Faria's significant beneficial ownership of 88.3% of common shares aligns his interests closely with those of other shareholders.
• The grant of performance-based stock options provides a strong incentive for the CEO to drive substantial share price appreciation, with vesting tied to ambitious VWAP targets ranging from $10.97 to $25.59.

Negatives

• The high concentration of beneficial ownership by a single individual (88.3%) could potentially impact market liquidity for the common shares.

Risks

• The vesting of the 471,208 stock options is entirely dependent on the Issuer's common stock achieving specific volume-weighted average price (VWAP) thresholds ranging from $10.97 to $25.59, which are subject to market performance and company execution.

Future Outlook

The vesting schedule for the CEO's stock options indicates an expectation of significant future share price appreciation, with volume-weighted average price targets set between $10.97 and $25.59.

Management Comments

• Management's decision to grant performance-based stock options to the CEO demonstrates a commitment to aligning executive incentives with long-term shareholder value creation.

Industry Context

This filing primarily concerns an individual's beneficial ownership and executive compensation structure, rather than broader industry trends. However, performance-based equity grants are a common mechanism across industries to incentivize executive performance and align management interests with shareholder value.

Corporate Governance

Related Party Transactions

• Grant of 471,208 stock options to Daniel Reis-Faria, the Chief Executive Officer of the Issuer.

Stakeholder Impact

• Shareholders: Potential for increased share price due to CEO incentives, but also potential future dilution risk from option exercise.
• Management: CEO's compensation is now more directly tied to the company's stock performance, providing a strong incentive for achieving growth targets.

Next Steps

• Monitoring the company's share price performance against the specified VWAP thresholds for option vesting.

Key Dates

Recommendation

The filing details a significant performance-based stock option grant to the CEO, Daniel Reis-Faria, who already holds a substantial 88.3% stake. This creates strong alignment between management and shareholder interests, incentivizing future share price growth. However, the ambitious VWAP vesting targets (up to $25.59) indicate a need for substantial future performance, and the filing alone does not provide enough fundamental data to warrant a 'buy' or 'sell' recommendation. A 'hold' position is prudent to observe how the company progresses towards these targets and to assess broader financial health.

Keywords

Flora Growth Corp., Daniel Reis-Faria, Schedule 13D, Stock Options, Beneficial Ownership, CEO Compensation, Equity Incentive, VWAP, Corporate Governance